Interferons‐beta versus glatiramer acetate for relapsing‐remitting multiple sclerosis

BACKGROUND: Interferons‐beta (IFNs‐beta) and glatiramer acetate (GA) were the first two disease‐modifying therapies (DMTs) approved 20 years ago for the treatment of multiple sclerosis (MS). DMTs' prescription rates as first or switching therapies and their costs have both increased substantial...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cochrane Database Syst Rev
Hlavní autoři: La Mantia, Loredana, Di Pietrantonj, Carlo, Rovaris, Marco, Rigon, Giulio, Frau, Serena, Berardo, Francesco, Gandini, Anna, Longobardi, Anna, Weinstock‐Guttman, Bianca, Vaona, Alberto
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Ltd 2016
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6464642/
https://ncbi.nlm.nih.gov/pubmed/27880972
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD009333.pub3
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky